Compare JPMorgan Chase & Co (JPM) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Neurocrine Biosciences Inc — how do they compare? JPMorgan Chase & Co trades at $344.85 (market cap $900.78B), while Neurocrine Biosciences Inc trades at $177.28 (market cap $17.40B). The key difference: JPMorgan Chase & Co is far larger — about 51.8× Neurocrine Biosciences Inc's market cap, and JPMorgan Chase & Co pays a 1.77% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| JPM | NBIX | |
|---|---|---|
Market Cap | $900.78B | $17.40B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $346.91 | $180.55 |
52-Week Low | $282.84 | $123.10 |
Dividend Yield | 1.77% | — |
Enterprise Value | — | $16.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $345.10, up 1.17% on the day, with strong technical momentum as the stock approaches resistance at $347. The company reported mixed Q4 2025 earnings but beat expectations in Q1 and Q2 2026, with revenue growing to $181.85 billion in 2025. Analyst sentiment remains positive with a consensus price target of $372.73, representing 8% upside potential from current levels.
JPMorgan demonstrates solid fundamentals with a reasonable P/E of 14.52 and strong net income margin of 33.4%. However, negative operating cash flow of -$147.78 billion in 2025 and geopolitical risks highlighted by CEO Jamie Dimon present headwinds. The stock offers value for long-term investors but faces near-term volatility from earnings uncertainty and macroeconomic concerns.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.
Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
